Abstract:Choosing antithrombotic therapy for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) is challenging. Oral anticoagulation is indicated to prevent stroke and systemic embolism in patients with atrial fibrillation but has not been shown to prevent stent thrombosis and is generally not indicated for secondary prevention after acute coronary syndrome. 1-3 Dual antiplatelet therapy is proven to reduce the incidence of recurrent ischemic events and stent thrombosis but is less effective in reducing the incidence of cardioembolic stroke associated with atrial fibrillation. 2-4 The combination of antithrombotic agents, particularly triple therapy with oral anticoagulation and dual antiplatelet therapy, increases the risk of bleeding. 5-7 Thus, an oral antithrombotic regimen with an acceptable benefit–risk profile would be useful in the treatment of patients with atrial fibrillation and concomitant acute coronary syndrome or PCI. Regimens including non–vitamin K antagonist oral anticoagulants appear to offer a number of advantages over vitamin K antagonists, including the potential for less bleeding. 8 Two trials evaluated standard or reduced doses of oral anticoagulants (of dabigatran and rivaroxaban, respectively) in patients with atrial fibrillation who were undergoing PCI, and both trials showed a lower incidence of bleeding with new oral anticoagulant regimens without aspirin than with vitamin K antagonist regimens that included aspirin. 9,10 Neither trial was designed to assess whether the lower incidence of bleeding was due to the use of the standard or reduced doses of the new oral anticoagulants or to the removal of aspirin therapy. We conducted the AUGUSTUS trial (a two-by-two factorial, randomized, controlled clinical trial) to assess the safety and efficacy of standard-dose apixaban as compared with a vitamin K antagonist and of low-dose aspirin as compared with placebo, on a background of concomitant P2Y 12 inhibitor therapy for 6 months in patients with atrial fibrillation and recent acute coronary syndrome or PCI. The trial was designed and led by an academic steering committee whose members were responsible for the conduct of the trial. The Duke Clinical Research Institute (DCRI, Durham, NC) was the academic coordinating center. The trial was sponsored by Bristol-Myers Squibb and Pfizer. The trial protocol (available with the full text of this article at NEJM.org) and all subsequent amendments were approved by national regulatory agencies in participating countries and by institutional review boards or ethics committees at participating sites. An independent data and safety monitoring board reviewed unblinded patient-level data at regular intervals during the trial. Although Bristol-Myers Squibb assisted with data management, all the statistical analyses were performed independently at the DCRI. The initial draft of the manuscript was written by the first author and revised on the basis of comments from the other authors. All the authors vouch for the adherence of the trial to the protocol, and the first, second, and last authors vouch for the accuracy and completeness of the data and analysis. No one who is not an author contributed to writing the manuscript. The committee members and participating investigators are listed in the Supplementary Appendix , available at NEJM.org. The trial rationale and design have been published previously. 11 In brief, AUGUSTUS was a prospective, multicenter, two-by-two factorial, randomized clinical trial comparing apixaban with a vitamin K antagonist and comparing aspirin with placebo in patients with atrial fibrillation who had a recent acute coronary syndrome or underwent PCI (or both). Patients who met all the following criteria were eligible for inclusion: an age of at least 18 years; previous, persistent, permanent, or paroxysmal atrial fibrillation and planned long-term use of an oral anticoagulant; recent acute coronary syndrome or PCI; and planned use of a P2Y 12 inhibitor for at least 6 months. Patients who were using anticoagulation for other conditions (e.g., prosthetic valves, venous thromboembolism, and mitral stenosis) were not eligible. Other key exclusion criteria were severe renal insufficiency, a history of intracranial hemorrhage, recent or planned coronary-artery bypass graft surgery, coagulopathy or ongoing bleeding, and contraindication to a vitamin K antagonist, apixaban, all P2Y 12 inhibitors, or aspirin. All the patients provided written informed consent before -Abstract Truncated-

IMPACT OF A MULTIFACETED EDUCATIONAL INTERVENTION ON ORAL ANTICOAGULATION (OAC) USE IN ATRIAL FIBRILLATION (AF) PATIENTS ACCORDING TO ASPIRIN USE AT BASELINE: INSIGHTS FROM IMPACT-AF TRIAL

A Multifaceted Intervention to Improve Treatment with Oral Anticoagulants in Atrial Fibrillation (IMPACT-AF): an International, Cluster-Randomised Trial.

A Clustered Randomized Trial to IMProve Treatment with AntiCoagulanTs in Patients with Atrial Fibrillation (IMPACT-AF): Design and Rationale

Effects of intensive, targeted education by pharmacists on anticoagulant patients with atrial fibrillation: a multicentre randomized controlled trial from China

Regional Differences in Presentation and Antithrombotic Treatment of Patients with Atrial Fibrillation: Baseline Characteristics from a Clustered Randomized Trial to IMProve Treatment with AntiCoagulanTs in Patients with Atrial Fibrillation (IMPACT-AF).

Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS

Oral anti-coagulants use in Chinese hospitalized patients with atrial fibrillation

A targeted educational intervention increases oral anticoagulation rates in high-risk atrial fibrillation patients

Understanding the barriers to using oral anticoagulants among long-term aspirin users with atrial fibrillation – a qualitative study

Double-blind, placebo-controlled randomised clinical trial to evaluate the effect of ASPIRIN discontinuation after left atrial appendage occlusion in atrial fibrillation: protocol of the ASPIRIN LAAO trial

Patients with Atrial Fibrillation are Unlikely to Benefit from Aspirin Monotherapy

Impact of a Focused Approach for Discharge Teaching Regarding the Use of Aspirin as Anticoagulant After Joint Replacement Surgery

Outcomes in Atrial Fibrillation Patients on Combined Warfarin & Antiarrhythmic Therapy.

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy

Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF

Anticoagulant and Antiplatelet therapy for the prevention of stroke in AF with arterial origin stroke: a meta-analysis.

Association between aspirin and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study based on mimic-IV database

The Impact of Changing Antithrombotic Management in Patients With Atrial Fibrillation and Ischemic Cerebrovascular Events Despite Anticoagulation

Comprehensive systematic review and meta-analysis on anticoagulants and aspirin for stroke prevention in non-valvular atrial fibrillation patients.

Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention